Underlying pharmacology of brain tumor drug treatment response and failure
Ended Awarded Last action
- Contract number
- 75N91018F00078
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,367,461
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $5,367,461.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $5,367,461 |
About this award
This is a $5,367,461.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for research related to the "Underlying Pharmacology of Brain Tumor Drug Treatment Response and Failure." It has a completion date of September 23, 2023. The contract does not have a set-aside designation.
Leidos Biomedical Research, as the prime contractor, has subcontracted work to Government Scientific Source Inc. for a Chromium X Single Cell Gene Expression Instrument, and to Carl Zeiss Microscopy, LLC for a Zeiss Axio Scan 7 Microscope System. Leidos Biomedical Research holds an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with NCI to serve as a Federally Funded Research and Development Center (FFRDC), providing a broad range of biomedical research and facilities support services.
Quick answers
Who was awarded contract 75N91018F00078?
75N91018F00078 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2018.
How much is contract 75N91018F00078 worth?
The government has obligated $5,367,461 on 75N91018F00078.
Is contract 75N91018F00078 an order under another contract?
Yes. 75N91018F00078 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00078 competed?
The extent of competition for 75N91018F00078 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award